{"entity":{"type":"insider","cik":"0001724939","url":"/insider/0001724939","json_url":"/insider/0001724939.json","name":"Flagship V VentureLabs Rx Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":6,"first":"2018-05-15","last":"2023-06-08","span_basis":"filed_date"},"name_variants":[{"name":"Flagship V VentureLabs Rx Fund, L.P.","source":"filing","n_filings":6,"first_seen":"2018-05-15","last_seen":"2023-06-08"}],"transactions":[{"id":8694528,"accession":"0000899243-23-014953","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-23-014953","line_url":"/filing/0000899243-23-014953","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship V VentureLabs Rx Fund, L.P.","owner_display_name":"Flagship Ventures Fund V General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":6.2397,"price_display":"6.24","price_state":"stated","total_value":1247940.0,"total_display":"1,247,940.00","total_whole":"1,247,940","shares_owned_after":10743293.0,"shares_owned_after_display":"10,743,293","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-07","filed_date":"2023-06-08","scope":"insider","n_lines":2},{"id":8694523,"accession":"0000899243-23-014953","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-014953","line_url":"/filing/0000899243-23-014953","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship V VentureLabs Rx Fund, L.P.","owner_display_name":"Flagship Ventures Fund V General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":203758.0,"shares_display":"203,758","price_per_share":6.3061,"price_display":"6.31","price_state":"stated","total_value":1284918.3238,"total_display":"1,284,918.32","total_whole":"1,284,918","shares_owned_after":10920533.0,"shares_owned_after_display":"10,920,533","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-06","filed_date":"2023-06-08","scope":"insider","n_lines":2},{"id":8135662,"accession":"0000899243-23-013992","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-013992","line_url":"/filing/0000899243-23-013992","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship V VentureLabs Rx Fund, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":82000.0,"shares_display":"82,000","price_per_share":6.2265,"price_display":"6.23","price_state":"stated","total_value":510573.0,"total_display":"510,573.00","total_whole":"510,573","shares_owned_after":11101994.0,"shares_owned_after_display":"11,101,994","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-26","filed_date":"2023-05-26","scope":"insider","n_lines":2},{"id":8135654,"accession":"0000899243-23-013992","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-23-013992","line_url":"/filing/0000899243-23-013992","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship V VentureLabs Rx Fund, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":115372.0,"shares_display":"115,372","price_per_share":6.3522,"price_display":"6.35","price_state":"stated","total_value":732866.0184,"total_display":"732,866.02","total_whole":"732,866","shares_owned_after":11174664.0,"shares_owned_after_display":"11,174,664","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-26","scope":"insider","n_lines":2},{"id":8135647,"accession":"0000899243-23-013992","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-013992","line_url":"/filing/0000899243-23-013992","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship V VentureLabs Rx Fund, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":347870.0,"shares_display":"347,870","price_per_share":6.5652,"price_display":"6.57","price_state":"stated","total_value":2283836.124,"total_display":"2,283,836.12","total_whole":"2,283,836","shares_owned_after":11276909.0,"shares_owned_after_display":"11,276,909","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-24","filed_date":"2023-05-26","scope":"insider","n_lines":2},{"id":6414741,"accession":"0000899243-22-031404","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-031404","line_url":"/filing/0000899243-22-031404#line-2","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship V VentureLabs Rx Fund, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":722590.0,"shares_display":"722,590","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":1865767.0,"shares_owned_after_display":"1,865,767","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-16","scope":"insider"},{"id":6414737,"accession":"0000899243-22-031404","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-031404","line_url":"/filing/0000899243-22-031404#line-1","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship V VentureLabs Rx Fund, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":210743.0,"shares_display":"210,743","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":1188920.0,"shares_owned_after_display":"1,188,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-16","scope":"insider"},{"id":5037920,"accession":"0000899243-21-031797","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-21-031797","line_url":"/filing/0000899243-21-031797","is_derivative":false,"issuer_cik":"0001400240","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001400240","owner_cik":null,"owner_name":"Flagship V VentureLabs Rx Fund, L.P.; Flagship VentureLabs V Manager LLC; Flagship VentureLabs V LLC; Flagship Pioneering Inc.; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC","owner_display_name":"Flagship V VentureLabs Rx Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1176469.0,"shares_display":"1,176,469","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":19999973.0,"total_display":"19,999,973.00","total_whole":"19,999,973","shares_owned_after":5514707.0,"shares_owned_after_display":"5,514,707","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-05","scope":"insider","n_lines":3},{"id":2101803,"accession":"0000899243-20-028807","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-20-028807","line_url":"/filing/0000899243-20-028807#line-7","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship V VentureLabs Rx Fund, L.P.; AFEYAN NOUBAR; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC","owner_display_name":"Flagship V VentureLabs Rx Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":165000.0,"shares_display":"165,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2475000.0,"total_display":"2,475,000.00","total_whole":"2,475,000","shares_owned_after":1143177.0,"shares_owned_after_display":"1,143,177","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-16","filed_date":"2020-10-20","scope":"insider"},{"id":6007977,"accession":"0000899243-18-013013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-013013","line_url":"/filing/0000899243-18-013013#line-2","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship V VentureLabs Rx Fund, L.P.; KANIA EDWIN M JR; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship VentureLabs V LLC; Flagship Ventures Fund V General Partner LLC; Nutritional Health Disruptive Innovation Fund, L.P.; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Nutritional Health Side Fund, L.P.","owner_display_name":"Flagship V VentureLabs Rx Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":281250.0,"shares_display":"281,250","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":18233403.0,"shares_owned_after_display":"18,233,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-11","filed_date":"2018-05-15","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001770121","name":"Sana Biotechnology, Inc.","url":"/issuer/0001770121","role":"Ten percent owner","n_filings":2,"first_seen":"2023-05-26","last_seen":"2023-06-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001659352","name":"Codiak BioSciences, Inc.","url":"/issuer/0001659352","role":"Ten percent owner","n_filings":2,"first_seen":"2020-10-20","last_seen":"2022-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001850838","name":"Omega Therapeutics, Inc.","url":"/issuer/0001850838","role":"Ten percent owner","n_filings":1,"first_seen":"2021-08-05","last_seen":"2021-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001694665","name":"Evelo Biosciences, Inc.","url":"/issuer/0001694665","role":"Ten percent owner","n_filings":1,"first_seen":"2018-05-15","last_seen":"2018-05-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001724939","retrieved_at":"2026-08-23T07:04:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}